A5003698195- Cutaneous Melanoma Detection and Management
- BRCA gene mutations in cancer
- Extracellular vesicles in disease
- Global Cancer Incidence and Screening
- T-cell and Retrovirus Studies
- Ferroptosis and cancer prognosis
- Cancer Genomics and Diagnostics
- Animal Disease Management and Epidemiology
- Nutrition, Genetics, and Disease
- Sarcoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Viral-associated cancers and disorders
- Nonmelanoma Skin Cancer Studies
- Cancer survivorship and care
- Vascular Tumors and Angiosarcomas
- RNA modifications and cancer
- Global Health Workforce Issues
- Genetic Associations and Epidemiology
- Economic and Financial Impacts of Cancer
- Travel-related health issues
- Cancer Risks and Factors
- CAR-T cell therapy research
- Health and Medical Research Impacts
- Lung Cancer Diagnosis and Treatment
- Breast Lesions and Carcinomas
University of Vermont Medical Center
2019-2025
Centre for the Observation and Modelling of Earthquakes, Volcanoes and Tectonics
2024
University of Vermont
2022-2024
Massachusetts General Hospital
2017-2020
Harvard University
2018
MGH Institute of Health Professions
2018
Brigham and Women's Hospital
2017
Hospital of the University of Pennsylvania
2015
University of Pennsylvania
2013
Importance Active monitoring for low-risk ductal carcinoma in situ (DCIS) of the breast has been proposed as an alternative to guideline-concordant care, but safety this approach is unknown. Objective To compare rates invasive cancer patients with DCIS receiving active vs care. Design, Setting, and Participants Prospective, randomized noninferiority trial enrolling 995 women aged 40 years or older a new diagnosis hormone receptor–positive grade 1 2 without at 100 US Alliance Cancer...
Plasma-derived extracellular vesicles potentially enable prediction and tracking of immunotherapy response.
Importance Active monitoring (AM) for low-risk ductal carcinoma in situ (DCIS) has been considered as a potential alternative to guideline-concordant care (GCC; inclusive of surgery with or without radiation). Reported data comparing patient-reported outcomes (PROs) between GCC and AM DCIS are lacking. Objective To compare PROs at baseline over time patients randomized receive either GCC. Design, Setting, Participants This prespecified secondary outcome analysis used prospectively collected...
Abstract Background Nodal surveillance (NS) has overtaken completion lymphadenectomy as the preferred management for sentinel node-positive (SLN+) melanoma, but requires frequent exams and nodal ultrasound (US). Social determinants of health (SDoH) may affect US adherence in real-world populations, evaluation these potential impacts is needed. Methods Adults with SLN+ melanoma diagnosed from July 2017 to December 2019 who received NS at nine cancer centers were identified retrospectively....
Background The impact of age on breast cancer risk model calculations at the population level has not been well documented. Methods Retrospective analysis formal assessment in 36 542 females ages 40-84 a single institution from 02/2007 to 12/2009. Five-year and lifetime risks were calculated using Gail, Tyrer-Cuzick version 6 (TC6), 7 (TC7), BRCAPRO, Claus models. Risk BRCA mutation was TC6, TC7, Myriad. Eligibility for testing assessed NCCN guidelines. Descriptive analyses performed trends...
Abstract There is a critical need for robust and minimally invasive biomarkers predicting monitoring tumor progression response to treatment. Transcriptomes of plasma-derived exosomes (PDEs) are suitable candidates fulfill such role, since they contain subtranscriptome their cell origin, and, nearly all types secrete exosomes, this allows the potential multiple concurrently. However, major issue preventing widespread adoption exosome as that observed plasma actually result from mixture...
Talimogene laherparepvec (T-VEC) is currently the only United States Food and Drug Administration-approved intralesional therapy for advanced melanoma. Recent studies have assessed integration of T-VEC with systemic immunotherapy, though response remains variable. Therefore, we sought to identify factors associated by conducting a retrospective, single-center analysis involving melanoma patients treated T-VEC. In present study, recorded demographic clinicopathological data, details...
Abstract Background: Modulation of the PD-1/PD-L1 axis in melanoma is critical importance both setting targeted therapy treatment, as well newer trials combining with checkpoint blocking antibodies. BRAF inhibition has been shown to increase PD-L1 expression tumors. Exosomes are circulating microvesicles that contain a subtranscriptome and/or subproteome their cell origin, including tumor cells and immune cells. We evaluated exosomal protein effect inhibitor (BRAFi) treatment on levels....
BACKGROUND Recent advances in diagnostic and therapeutic modalities have made oncologic care ever more challenging, multidisciplinary tumor boards (MTBs) are increasingly being used as a forum to discuss coordinate for complex oncology patients. Literature on the use of MTBs specific cutaneous dermatologic surgery remains limited. OBJECTIVE To share our experiences with at University Vermont Medical Center (UVMMC). METHODS We describe formation, timing, participation, clinical discussion,...
Abstract Background: Over-expression of the receptor tyrosine kinase ErbB2 (HER-2) has been widely implicated in malignant transformation, cell survival, motility and invasion breast cancers. Intermediate expression HER-2 identified luminal cancer stem cells. over-expression down regulates major histocompatibility complex class I molecules (MHCI) Results: We investigated various expressing lines measured HLA A-2 MHC expression. High Her-2 SKBR3 SKOVA3 intermediate MCF7 demonstrated extremely...
Abstract Molecular and immunologic studies analyzing tumor samples have failed to find a robust reliable predictive marker of responsiveness immune checkpoints. Exosomes are circulating microvesicles that contain subtranscriptome their cell origin. They produced by cells been shown be mediators responses in cancer. To examine the role peripheral-blood (PB) derived exosomal transcriptomic signatures, we performed microarray analysis on N=99 from both PB-derived exosomes biopsies N=39 (N=25...